More than 130 million people worldwide chronically infected with
hepatitis C virus (HCV) are at risk of developing severe liver disease.
Antiviral treatments are only partially effective against HCV infection,
and a vaccine is not available. Development of more efficient therapies
has been hampered by the lack of a small animal model. Building on the
observation that CD81 and occludin (OCLN) comprise the minimal set of
human factors required to render mouse cells permissive to HCV entry,
we previously showed that transient expression of these two human genes
is sufficient to allow viral uptake into fully immunocompetent inbred
mice.
Here we demonstrate that transgenic mice stably expressing human CD81
and OCLN also support HCV entry, but innate and adaptive immune
responses restrict HCV infection in vivo. Blunting antiviral
immunity in genetically humanized mice infected with HCV results in
measurable viraemia over several weeks. In mice lacking the essential
cellular co-factor cyclophilin A (CypA), HCV RNA replication is markedly
diminished, providing genetic evidence that this process is faithfully
recapitulated. Using a cell-based fluorescent reporter activated by the
NS3-4A protease we visualize HCV infection in single hepatocytes in vivo. Persistently infected mice produce de novo
infectious particles, which can be inhibited with directly acting
antiviral drug treatment, thereby providing evidence for the completion
of the entire HCV life cycle in inbred mice. This genetically humanized
mouse model opens new opportunities to dissect genetically HCV infection
in vivo and provides an important preclinical platform for
testing and prioritizing drug candidates and may also have utility for
evaluating vaccine efficacy.
Enlace al artículo
Microbiota-liberated host sugars facilitate post-antibiotic expansion of enteric pathogens
The human
intestine, colonized by a dense community of resident microbes, is a
frequent target of bacterial pathogens. Undisturbed, this intestinal
microbiota provides protection from bacterial infections. Conversely,
disruption of the microbiota with oral antibiotics often precedes the
emergence of several enteric pathogens1, 2, 3, 4.
How pathogens capitalize upon the failure of microbiota-afforded
protection is largely unknown. Here we show that two
antibiotic-associated pathogens, Salmonella enterica serovar Typhimurium (S. typhimurium) and Clostridium difficile, use a common strategy of catabolizing microbiota-liberated mucosal carbohydrates during their expansion within the gut. S. typhimurium
accesses fucose and sialic acid within the lumen of the gut in a
microbiota-dependent manner, and genetic ablation of the respective
catabolic pathways reduces its competitiveness in vivo. Similarly, C. difficile expansion is aided by microbiota-induced elevation of sialic acid levels in vivo. Colonization of gnotobiotic mice with a sialidase-deficient mutant of Bacteroides thetaiotaomicron, a model gut symbiont, reduces free sialic acid levels resulting in C. difficile
downregulating its sialic acid catabolic pathway and exhibiting
impaired expansion. These effects are reversed by exogenous dietary
administration of free sialic acid. Furthermore, antibiotic treatment of
conventional mice induces a spike in free sialic acid and mutants of
both Salmonella and C. difficile that are unable to
catabolize sialic acid exhibit impaired expansion. These data show that
antibiotic-induced disruption of the resident microbiota and subsequent
alteration in mucosal carbohydrate availability are exploited by these
two distantly related enteric pathogens in a similar manner. This
insight suggests new therapeutic approaches for preventing diseases
caused by antibiotic-associated pathogens.